CORT Form 144 Files Proposed Sale After Option Exercise

Rhea-AI Filing Summary

Form 144 filed for Corcept Therapeutics, Inc. (CORT) reports a proposed sale of 20,000 common shares to be executed on 09/02/2025 through Stifel Nicolaus & Company, Inc. The shares were acquired the same day by stock option exercise and paid in cash. The filing lists total outstanding shares of 105,370,000 and an aggregate market value for the proposed sale of $1,394,400.00. The notice also discloses multiple sales by the same holder, William Guyer, during the prior three months, including a sale of 35,007 shares on 08/08/2025 for $2,512,452.00. The filer certifies there is no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider sale of newly exercised options with recent prior dispositions; not clearly material to CORT's capital structure.

The filing shows a proposed disposal of 20,000 common shares acquired by option exercise and paid in cash, with an indicated aggregate market value of $1.394M against 105.37M shares outstanding, representing roughly 0.02% of shares outstanding. Recent historical sales by the same holder are disclosed, including several transactions in June–August 2025. From a market-impact perspective, the size of the proposed sale is small relative to total shares outstanding, suggesting limited direct dilution or supply shock. The pattern of periodic sales by an insider is relevant for sentiment analysis but is not, on its face, a material capital change.

Compliance / Corporate Governance Expert

TL;DR: Filing appears procedurally complete; seller attests no undisclosed material information and cites option exercise as acquisition.

The Form 144 includes required elements: broker identification, number of shares, acquisition date and nature (stock option exercise), payment method, and prior three months of sales by the same person. The statement that there is no material nonpublic information is present. There is no indication of a Rule 10b5-1 plan adoption date on the form. For compliance review, documentation of the option exercise and cash payment should be maintained to support the representations on the filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Company Inc. 501 N. Broadway St. Louis MO 63102	20000	1394400.00	105370000	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Stock Option Exercise	Corcept Therapeutics Inc.			20000	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	06/10/2025	20000	1448475.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/01/2025	100	7351.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/17/2025	4379	321774.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/18/2025	500	36721.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	08/05/2025	14	1005.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	08/08/2025	35007	2512452.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Corcept Therapeutics (CORT) report?

The Form 144 reports a proposed sale of 20,000 common shares to be sold on 09/02/2025 through Stifel Nicolaus & Company, Inc.

How were the 20,000 shares acquired according to the filing?

The shares were acquired on 09/02/2025 via a stock option exercise and paid for in cash on that date.

Who is the seller named on the Form 144 and what prior sales are disclosed?

The seller is listed as William Guyer; prior sales in the past three months include transactions on 06/10/2025, 07/01/2025, 07/17/2025, 07/18/2025, 08/05/2025, and 08/08/2025.

What is the aggregate market value and shares outstanding noted on the filing?

The filing shows an aggregate market value for the 20,000 shares of $1,394,400.00 and 105,370,000 shares outstanding.

Does the Form 144 indicate the seller is relying on a 10b5-1 plan?

No date of plan adoption or instruction under Rule 10b5-1 is provided on the filing.